The good & the bad

[Little Birdie]

Okay Q2 revenue numbers (not great, not bad)
No new guidance given (too soon, not enough sales data from restructured force & new CFO needs his input)

 

[anonymous]

This is a pharma sales board stock twat goober.

GTFO

Okay Q2 revenue numbers (not great, not bad)
No new guidance given (too soon, not enough sales data from restructured force & new CFO needs his input)

 

[anonymous]

This is a pharma sales board stock twat goober.

GTFO

Correct me if I am wrong. But Q2 revenue (aka sales) and forward Guidance (sales forecast) do in fact relate to a "pharma sales board" as you mention above. What am I missing here ??

 

[anonymous]

You are wrong. GTFO!

 

[anonymous]

No guidance provided but some serious negative looking news in $PTX earnings such as "Discontinued the development of a new formulation of Treximet due to a delay in development timeline which significantly reduced our expected return on investment...Treximet net sales decreased by $7.7 million, or 30%, during the three months ended June 30, 2016 compared to the three months ended June 30, 2015. Silenor net sales decreased by $1.8 million, or 30%, during the three months ended June 30, 2016 compared to the three months ended J

 

[anonymous]

and a number of its creditors that its debt obligations will need to be amended or exchanged for new debt and/or equity securities, and some debt holders may have little or no recovery on their investment. We continue to explore and consider alternatives, which may include a possible reorganization under US bankruptcy laws or another jurisdiction, so that we can ride out this very difficult cycle with feasible prospects for strong, long-term success."